QIBA Lung Nodule Assessment in CT Screening Writing Group

27 February 2014 at 3 PM CT Tracking and to-dos (not formal notes)

In attendance:

Samuel G. Armato, III, PhD (Co-Chair) David S. Gierada, MD (Co-Chair) James L. Mulshine, MD (Co-Chair) Andrew J. Buckler, MS Michael McNitt-Gray, PhD Jenifer Siegelman, MD, MPH Mario Silva, MD Daniel Sullivan, MD David Yankelevitz, MD **RSNA:** Joe Koudelik Julie Lisiecki

Action items for next call:

- Mr. Buckler to discuss "compliance" on next call, e.g., the spatial resolution issue across FOV
 - Mr. Buckler to work with Dr. Gierada on claims template wording offline
- Ongoing Profile work to continue amongst participants via email.
 - \circ $\hfill Need to harmonize claims text with appendix and compliance items$
- Dr. McNitt-Gray to follow up with Dr. Fuld regarding CT scanner protocols for different models
- Possible discussion of topical issue raised by Dr. Mulshine regarding CMS reimbursements for screenings
- Dr. Mulshine to consider inviting Dr. Kazerooni to speak to the group on a future call.
- Proposals encouraged for next round of NIBIB funding by April 7th

Next call: QIBA Lung Nodule Assessment in CT Screening Writing Group, Thursday, March 13, 2014, 3 pm CT

Discussion topics continuing:

- The Profile is fairly well edited, with only claims and compliance remaining for discussion.
- Appendix D and 510K FDA approval were also topics of discussion.
- What is needed specifically to use low-dose techniques
- Adoption of up to 2.5 slice thickness from the NLST trial
- Dr. McNitt-Gray to talk with Dr. Fuld re: ideas regarding recon, etc., for manufacturer input
- Possibility of a UPICT-style low-dose nodule protocol, with information provided by AAPM manufacturer collaborators